T315I, more or less, predicts for major molecular response: the devil is in the details!

被引：2
作者：
Mauro, Michael J. [1 ]
机构：
[1] Oregon Hlth & Sci Univ, Knight Canc Inst, Ctr Hematol Malignancies, Portland, OR 97201 USA
来源：
HAEMATOLOGICA | 2013年 / 98卷 / 05期
关键词：
CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE; ABL GENE; RESISTANCE; INHIBITOR; MUTATIONS; CML;
D O I：
10.3324/haematol.2013.084251
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：665 / 666
页数：2
相关论文
共 50 条
  • [1] Persistent major molecular response to nilotinib therapy in a patient with chronic myeloid leukemia harboring ABL gene T315I mutation
    Zhou, Jinyi
    Qu, Qi
    Chen, Suning
    Xu, Yang
    Shen, Hongjie
    Cen, Jiannong
    Wu, Depei
    LEUKEMIA & LYMPHOMA, 2015, 56 (11) : 3207 - 3209
  • [2] The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia
    Lange, Thoralf
    Ernst, Thomas
    Gruber, Franz X.
    Maier, Jacqueline
    Cross, Michael
    Mueller, Martin C.
    Niederwieser, Dietger
    Hochhaus, Andreas
    Pfirrmann, Markus
    HAEMATOLOGICA, 2013, 98 (05) : 714 - 717
  • [3] In Silico Molecular Modeling of Four New Afatinib Derived Molecules Targeting the Inhibition of the Mutated Form of BCR-ABL T315I
    Rocha, Kelvyn M. L.
    Nascimento, erica C. M.
    de Jesus, Rafael C. C.
    Martins, Joao B. L.
    MOLECULES, 2024, 29 (17):
  • [4] Rapid Quantitative Detection of the T315I Mutation in Patients With Chronic Myelogenous Leukemia
    Yin, Lihui
    Dittman, David
    Chenn, Anjen
    DIAGNOSTIC MOLECULAR PATHOLOGY, 2012, 21 (01) : 34 - 39
  • [5] Broad spectrum alkynyl inhibitors of T315I Bcr-Abl
    Deng, Xianming
    Lim, Sang Min
    Zhang, Jianming
    Gray, Nathanael S.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (14) : 4196 - 4200
  • [6] Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation
    Pemovska, Tea
    Johnson, Eric
    Kontro, Mika
    Repasky, Gretchen A.
    Chen, Jeffrey
    Wells, Peter
    Cronin, Ciaran N.
    McTigue, Michele
    Kallioniemi, Olli
    Porkka, Kimmo
    Murray, Brion W.
    Wennerberg, Krister
    NATURE, 2015, 519 (7541) : 102 - U225
  • [7] Recent Developments in the Third Generation Inhibitors of Bcr-Abl for Overriding T315I Mutation
    Lu, X. Y.
    Cai, Q.
    Ding, K.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (14) : 2146 - 2157
  • [8] Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation
    Jiang, Liang
    Wang, Yuting
    Li, Qian
    Tu, Zhengchao
    Zhu, Sihua
    Tu, Sanfang
    Zhang, Zhang
    Ding, Ke
    Lu, Xiaoyun
    ACTA PHARMACEUTICA SINICA B, 2021, 11 (05) : 1315 - 1328
  • [9] Screening and Activity Evaluation of Novel BCR-ABL/T315I Tyrosine Kinase Inhibitors
    Su, Jie
    Fu, Chenggong
    Wang, Shuo
    Chen, Xuelian
    Wang, Runan
    Shi, Huaihuai
    Li, Jiazhong
    Wang, Xin
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (20) : 2872 - 2894
  • [10] Crystal structure of the T315I mutant of abl kinase
    Zhou, Tianjun
    Parillon, Lois
    Li, Feng
    Wang, Yihan
    Keats, Jeff
    Lamore, Sarah
    Xu, Qihong
    Shakespeare, William
    Dalgarno, David
    Zhu, Xiaotian
    CHEMICAL BIOLOGY & DRUG DESIGN, 2007, 70 (03) : 171 - 181
12345